HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Effects of 5-year treatment with elcatonin and alfacalcidol on lumbar bone mineral density and the incidence of vertebral fractures in postmenopausal women with osteoporosis: a retrospective study.

Abstract
The purpose of this retrospective study was to compare the effects of long-term treatment (5 years) with elcatonin and alfacalcidol on bone mineral density (BMD) and the incidence of vertebral fractures in postmenopausal women with osteoporosis. Fifty-six osteoporotic women, more than 5 years after menopause and 58-79 years of age, were enrolled in the study and allocated to an elcatonin treatment group (20 units IM, weekly; n = 30) or an alfacalcidol treatment group (1 micro g/day, daily; n = 26). BMD of the lumbar spine (L2-L4) was measured by dual energy X-ray absorptiometry at baseline and every year for 5 years. There were no significant differences in age, body mass index, years since menopause, BMD, or number of prevalent vertebral fractures at baseline between the two groups. One-way analysis of variance with repeated measurements showed no significant longitudinal changes in BMD in either group, suggesting that both treatments sustained the BMD over 5 years. Two-way analysis of variance with repeated measurements also showed no significant differences in longitudinal changes in BMD between the two groups, suggesting that the effects of the two treatments on BMD were similar. However, the number of incident vertebral fractures per patient was significantly lower in the alfacalcidol treatment group than in the elcatonin treatment group (0.80 +/- 1.19 and 2.08 +/- 2.73, respectively; P < 0.05). These findings indicate that both treatments appeared to sustain lumbar BMD similarly over a 5-year period in postmenopausal women with osteoporosis, but alfacalcidol treatment may be superior to elcatonin treatment regarding the incidence of vertebral fractures. Further study with prospective observations are needed to confirm the results of the present study.
AuthorsJun Iwamoto, Tsuyoshi Takeda, Shoichi Ichimura, Mitsuyoshi Uzawa
JournalJournal of orthopaedic science : official journal of the Japanese Orthopaedic Association (J Orthop Sci) Vol. 7 Issue 6 Pg. 637-43 ( 2002) ISSN: 0949-2658 [Print] Japan
PMID12486466 (Publication Type: Comparative Study, Journal Article)
Chemical References
  • Hydroxycholecalciferols
  • Calcitonin
  • alfacalcidol
  • elcatonin
Topics
  • Aged
  • Bone Density (drug effects, physiology)
  • Calcitonin (analogs & derivatives, therapeutic use)
  • Dose-Response Relationship, Drug
  • Drug Administration Schedule
  • Female
  • Follow-Up Studies
  • Fractures, Spontaneous (prevention & control)
  • Humans
  • Hydroxycholecalciferols (therapeutic use)
  • Incidence
  • Lumbar Vertebrae (drug effects)
  • Middle Aged
  • Osteoporosis, Postmenopausal (complications, diagnostic imaging, drug therapy)
  • Probability
  • Radiography
  • Retrospective Studies
  • Risk Assessment
  • Spinal Fractures (epidemiology, etiology)
  • Time Factors
  • Treatment Outcome

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: